Department of Gastroenterology, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
Department of Geriatric Medicine, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara, Turkey.
Medicine (Baltimore). 2024 Nov 1;103(44):e40355. doi: 10.1097/MD.0000000000040355.
Cholecystectomy generally has no adverse effects on health. Studies demonstrating the association between metabolic diseases and long-term effects of cholecystectomy are increasing. preperitoneal fat thickness (PFT) is an important indicator of metabolic syndrome. Metabolic syndrome is a risk factor for sarcopenia. The aim of our study was to investigate the relationship between cholecystectomy and sarcopenia-visceral fat using the ISarcoPRM algorithm, which is an easy, reliable, and inexpensive method based on ultrasound measurement, to evaluate sarcopenia in patients with long-term previous cholecystectomy. This cross-sectional study included participants who had undergone cholecystectomy at least 5 years ago and a control group with similar characteristics. Sarcopenia was assessed using the ISarcoPRM algorithm, incorporating the sonographic thigh adjustment ratio (STAR), grip strength, and chair stand test (CST). Together with low STAR values (<1.0 for females and <1.4 for males), ow grip strength (<19 kg for females or <32 kg for males), and/or prolonged CST duration (≥12 seconds) were used to diagnose sarcopenia. Ultrasound was used to measure the visceral fat thickness. The investigation of sarcopenia and PFT values between individuals with and without cholecystectomy was planned. A total of 158 participants were included, including 89 post-cholecystectomy patients and 69 controls. Binary regression analysis revealed that cholecystectomy was positively associated with sarcopenia (OR = 2.788, 95% CI: 1.054-7.375, P = .039). However, when PFT was included, it was independently associated with sarcopenia (OR = 1.157, 95% CI: 1.067-1.254, P < .001), and the relationship with cholecystectomy disappeared (P > .05). PFT values of 10.0 mm or higher were associated with 5.875 times (95% CI: 2.035-16.961, P = .001) increased odds of sarcopenia. Sarcopenia was 2.8 times more frequent in patients who had undergone cholecystectomy than in those who had not, but this relationship was mediated by increased PFT. The risk of sarcopenia increased up to 5.875 times when the PFT exceeded 10 mm.
胆囊切除术一般不会对健康产生不良影响。越来越多的研究表明，代谢疾病与胆囊切除术的长期影响之间存在关联。腹膜前脂肪厚度（PFT）是代谢综合征的一个重要指标。代谢综合征是肌肉减少症的一个危险因素。我们的研究目的是通过使用基于超声测量的简单、可靠和廉价的 ISarcoPRM 算法，探讨胆囊切除术与内脏脂肪之间的关系，以评估长期接受胆囊切除术患者的肌肉减少症。这项横断面研究纳入了至少 5 年前接受过胆囊切除术的患者和具有相似特征的对照组。使用 ISarcoPRM 算法评估肌肉减少症，该算法纳入了超声大腿调整比值（STAR）、握力和坐站测试（CST）。低 STAR 值（女性<1.0，男性<1.4）、低握力（女性<19kg 或男性<32kg）和/或 CST 持续时间延长（≥12 秒）一起用于诊断肌肉减少症。使用超声测量内脏脂肪厚度。计划调查有和没有胆囊切除术的个体之间的肌肉减少症和 PFT 值。共纳入 158 名参与者，包括 89 名胆囊切除术后患者和 69 名对照组。二元回归分析显示，胆囊切除术与肌肉减少症呈正相关（OR=2.788，95%CI：1.054-7.375，P=0.039）。然而，当纳入 PFT 时，它与肌肉减少症独立相关（OR=1.157，95%CI：1.067-1.254，P<0.001），与胆囊切除术的关系消失（P>0.05）。PFT 值为 10.0mm 或更高与肌肉减少症的发生风险增加 5.875 倍（95%CI：2.035-16.961，P=0.001）相关。与未接受胆囊切除术的患者相比，接受胆囊切除术的患者肌肉减少症的发生率增加了 2.8 倍，但这种关系是由 PFT 的增加介导的。当 PFT 超过 10mm 时，肌肉减少症的发生风险增加到 5.875 倍。
